Coronary Artery Disease
Conditions
Keywords
Culprit plaques, Vulnerable Plaques, PET, calcification, inflammation
Brief summary
Cardiovascular disease is the leading cause of death in Scotland and the Western World. Approaches to improve the identification of vulnerable or ruptured coronary atherosclerotic plaques are urgently needed to help risk stratification, to identify patients for intensive therapies, and to provide novel biomarkers for the development of anti-atherosclerotic drug interventions. Using positron emission tomography, we have recently shown that sodium 18-fluoride uptake holds major promise as a novel marker of plaque vulnerability and rupture. Here we wish to characterise coronary atherosclerotic plaque using 128-multidetector computed tomography combined with 18-fluorodeoxyglucose and sodium 18-fluoride positron emission tomography and Virtual histology-intravascular ultrasound in 80 patients with stable and unstable coronary artery disease. This has the potential to provide an innovative and highly valuable translational model with which to test novel therapeutic interventions targeted at reducing atheroma and plaque rupture. This could have major implications for the future treatment of cardiovascular disease.
Interventions
None listed
Sponsors
University of Cambridge
University of Edinburgh
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Age \> or = 50 yrs. Patients with Acute coronary syndromes or stable coronary artery disease.
Exclusion criteria
Insulin dependent diabetes Inability or unwillingness to undergo computed tomography scanning Severe renal failure (serum creatinine \>250 µmol/L or estimated glomerular filtration rate \<30 mL/min) Known contrast allergy Inability to give informed consent. Females in child bearing age will undergo pregnancy test if pregnancy suspected. Participation in other research studies requiring exposure to further radiation (over and above mentioned in this study).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Patients with ACS have focal 18F-NaF uptake and high tissue to background ratio(TBR) and standardised uptake values (SUV) in the culprit vessels. | Within 1 month of index event | Using PET/CT, the investigators will assess if there is presence of focal uptake at the areas of plaque ruptures in patients presenting with ACS. Standardised uptake values and Tissue to Background ratios of the culprit vessels with be compared with non-culprit lesions. |
| What are the morphological characteristics of plaque with high 18F-NaF tissue to background ratio or standardised uptake value | 1 month | Using VH-IVUS, the investigators will look at the morphological characteristics of plaques that have higher SUVs and TBRs. Additional information about the plaque characteristics will be derived from CT coronary angiogram |
Secondary
| Measure | Time frame |
|---|---|
| Is there a co-relation between the two PET/CT tracers(18FDG and 18F NaF) as measured as Tissue to background ratio or standardised uptake value. | 1 month |
Other
| Measure | Time frame | Description |
|---|---|---|
| Is there a difference between the coronary and aortic TBR/SUVs in stable and unstable patients | 1 month | The investigators will look for differences in activity in stable angina and ACS patients using 18F-NaF and 18F-FDG |
| Will patients with higher 18F-NaF uptake as measured by SUV/TBR will have higher levels of cardiac biomarkers such as hsCRP or Troponin | 1 year | Blood collected from volunteers in the study will be analysed for inflammatory biomarkers such as hsCRP and Troponin |
Countries
United Kingdom
Outcome results
None listed